Albireo Pharma Inc (ALBO) Receives a Rating Update from a Top Analyst

By Carrie Williams

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Albireo Pharma Inc (ALBOResearch Report) yesterday. The company’s shares closed yesterday at $25.

According to, Baral is a top 100 analyst with an average return of 24.7% and a 46.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma Inc with a $59.50 average price target, a 138.0% upside from current levels. In a report issued on November 13, Needham also maintained a Buy rating on the stock with a $50 price target.


See today’s analyst top recommended stocks >>

Based on Albireo Pharma Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $14.03 million. In comparison, last year the company had a GAAP net loss of $6.51 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.